Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
Contenu
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Titre
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
Sujet
Description
The mRNA-1273 vaccine against SARS-CoV-2 elicited high neutralizing-antibody titers in phase 1 trial participants and has been shown to be highly efficacious in preventing symptomatic Covid-19 disease and severe disease.
Date
2021-02-17
Type
Citer ce document
Wu, Kai, Anne P. Werner, Matthew Koch, Angela Choi, Elisabeth Narayanan, Guillaume B. E. Stewart-Jones, Tonya Colpitts, Hamilton Bennett, Seyhan Boyoglu-Barnum, Wei Shi, Juan I. Moliva, Nancy J. Sullivan, Barney S. Graham, Andrea Carfi, Kizzmekia S. Corbett, Robert A. Seder, and Darin K. Edwards. 2021. "Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report." New England Journal of Medicine.
Accessibilité
Free online on NEJM.
Was this resource helpful?